Osteoarthritis, Osteoarthritis Thumbs
Conditions
Keywords
adipose stem cells, Rigenera protocol, trapeziometacarpal arthritis, microfragmented adipose tissue
Brief summary
The objective of this interventional study is the Change in the Michigan Hand Questionnaire (MHQ) score over time in subjects with Eaton Littler grade II and III trapeziometacarpal osteoarthritis. The main questions to be answered are: * primary outcomes: Differences in the change in the MHQ scale measured as a reduction in the score result of 12 points within 6 months from preoperative. * secondary outcomes: Change from baseline in hand function measured by grip strength (Gripstrength); Change from baseline in hand function by lateral grip strength (tippinch and tripodpinch); Change in the Visual Analogue Scale (VAS) pain scale before the procedure then after the procedure, at 1, 3 and 6 months; Safety and tolerance of the treatments.
Interventions
PROCEDUREadipose micro-grafts injection
Patients were positioned supine, and local anesthesia was administered. A small incision was made to introduce a blunt cannula attached to a Luer-lock 60-cc syringe. Klein sterile solution, containing saline and lidocaine, was injected into the subcutaneous fat layer of either the abdominal or thigh region. Subsequently, approximately 30 mL of adipose tissue was extracted. The collected lipoaspirate was processed under sterile conditions in a closed system using Rigenera® technology (HBW, Turin, Italy). Before injecting, the skin was sterilely dressed, and the injection of 2-3 mL of aMAT was performed into TMC joint with a superolateral approach, under fluoroscopic X-ray guidance and using a disposable 20G needle and a 3 mL Luer-Lock Syringe.
Sponsors
Azienda Ospedaliero, Universitaria Ospedali Riuniti
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent. 2. Male or female aged ≥ 40 and ≤ 75 years 3. Normal axial alignment 4. Eaton/Littler stage 2-3 5. MHQ pain scale 6. Willingness to participate in all scheduled follow-ups 7. Willingness to abstain from taking level 2 analgesics and opioids for the duration of the study. NSAIDs and Paracetamol are permitted.
Exclusion criteria
1. Pregnant and/or breastfeeding women. 2. If a woman, of childbearing age and the subject is not using a highly effective method of birth control and is not willing to use it during participation in the clinical trial. Highly effective methods of birth control include: combined hormonal contraception (containing estrogen and progestin) combined with ovulation inhibition (oral, intravaginal, transdermal); progestin-only hormonal contraception combined with ovulation inhibition (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence; 3. Intra-articular injection within 3 months of treatment. 4. Immunocompromised for reasons such as corticosteroid therapy, chemotherapy, antiangiogenic or immunosuppressive agents, or due to immunodeficiency syndromes 5. Previous hand surgery within the last 6 months 6. History of connective tissue disease, such as systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome or mixed connective tissue disease 7. Infections in the trapezium-metacarpal joint, skin disease or infections in the area of the injection site
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in hand and upper limb function measured by the Michigan Hand questionnaire | The MHQ will be administered at three key time points: before treatment, 3 months, and 6 months after the therapeutic intervention, in order to monitor clinical progress and treatment effectiveness. | The Michigan Hand Questionnaire (MHQ) is a validated instrument specifically designed to assess hand function and the impact of upper extremity conditions on quality of life. The questionnaire explores six main dimensions: general function, activities of daily living (ADL), pain, aesthetics, patient satisfaction, and work function. The score for each domain is converted to a scale of 0 to 100, where: 100 represents the best perceived functional outcome, 0 represents the worst outcome. For some subsections (such as pain), the scale is reversed to ensure correct interpretation of the scores. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of: 1. Change from baseline in hand function measured by grip strength 2. Change from baseline in hand function measured by lateral grip strength (tip pinch and tripod pinch) 3. Change in visual analogue scale of pain (VAS) over time 4.Safety | Three key time points: before treatment, 3 months, and 6 months after the therapeutic intervention. | 1. The grip strength of the treated hand is measured with the JAMAR manual hydraulic dynamometer in kilograms of pressure by taking the greatest force of three successive attempts with 15 seconds of rest between each attempt. 2. The lateral grip strength (tippinch: between the thumb and index finger; tripodpinch: between the thumb, index finger and middle finger) of the treated hand is measured with the mechanical grip meter in kilograms of pressure by taking the greatest force of three successive attempts with 15 seconds of rest between each attempt. 3. Differences in the pain scale measured as a reduction in pain perception. Pain in the treated joint will be assessed by a visual analogue scale that requires the patient to respond by placing a vertical line on a 100mm scale where 0 corresponds to no pain and 100 unbearable pain. 4. Evaluation of the safety and tolerability of the treatment, detected by examining the adverse events expected at local level. |
Countries
Italy
Outcome results
None listed